Antitumor activity and biodistribution of DHA-NLC formulation in sarcoma 180-bearing mice  

双氢青蒿素纳米结构脂质载体在荷S180瘤小鼠体内的抗肿瘤活性及生物分布研究(英文)

作　　者：张晓云[1] 乔华[2] 赵鹏[3] 倪京满[1] 史彦斌[1] 

机构地区：[1]兰州大学 药学院,甘肃兰州730000 [2]兰州大学第一医院药剂科,甘肃兰州730000 [3]兰州大学第一医院肿瘤科,甘肃兰州730000

出　　处：《Journal of Chinese Pharmaceutical Sciences》2013年第4期348-354,共7页中国药学（英文版）

基　　金：Fundamental Research Funds of Lanzhou University for the Central Universities (Grant No. lzujbky-2012-85);the Lanzhou Science and Technology Bureau (Grant No. 2012-2-80)

摘　　要：Lipid nanoparticles have become attractive for its prominent properties recent years. In this paper, in vivo anti-tumor efficacy of nanostructured lipid carrier of dihydroartemisinin （DHA-NLC） were evaluated in sarcoma 180-bearing mice model through intraperitoneal （i.p.） administration. In vivo biodistribution was also investigated in Kunming mice bearing S180. Results demonstrated that the intraperitoneally injected DHA-NLC could significantly inhibit tumor growth at the dose levels of 20, 40 and 80 mg/kg, and their inhibition rates were 71.24%, 79.20% and 85.74%, respectively. The biodistribution of DHA after intraperitoneal injection of DHA-NLC in S180-bearing mice is remarkably different from the DHA solution. Therefore, DHA encapsulated in NLC does demonstrate superior anticancer effect to DHA suspension on S 180-bearing mice at the same dose and displayed a dose-dependent antitumor efficacy.近年来脂质纳米粒由于其优越的特征备受青睐。本文通过腹腔注射评价了双氢青蒿素纳米结构脂质载体在荷S180瘤小鼠体内的抗肿瘤作用, 以及在荷S180昆明鼠内的生物分布研究。结果表明双氢青蒿素纳米结构脂质载体显著抑制了肿瘤的增长, 通过腹腔给药在20, 40和80mg/kg时肿瘤抑制率分别为71.24%, 79.20%和85.74%, 在荷S180小鼠体内静脉注射双氢青蒿素纳米结构脂质载体后, 药物的生物分布表明双氢青蒿素纳米结构脂质载体与双氢青蒿素溶液相比, 双氢青蒿素纳米结构脂质载体显示了明显不同的生物分布。因此, 本文实验结果确实证明了双氢青蒿素纳米结构脂质载体与双氢青蒿素普通混悬液相比, 在相同剂量下双氢青蒿素纳米结构脂质载体显示出更优越的抗肿瘤作用和剂量依赖性。

关 键 词：Nanostructured lipid carrier ANTITUMOR Sarcoma 180 BIODISTRIBUTION 

分 类 号：R96[医药卫生—药理学]